ReviewJournal of clinical medicine2024
Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients.Journal of clinical and translational hepatology · 2026Article
- Insulin Resistance as a Dynamic Correlate of Fibrosis Status in Chronic Hepatitis B: A Visit-Level Longitudinal Risk Stratification Framework.Life (Basel, Switzerland) · 2026Article
- Cut or Count? Evaluating Advanced Fibrosis Assessment Tools in MASH and Chronic Viral Hepatitis.Biomedicines · 2026Article
- Vitamin D deficiency in chronic hepatitis B across the disease spectrum: association with viral activity rather than hepatocellular carcinoma.BMC gastroenterology · 2026Article
- Performance of Serum-Based Non-Invasive Fibrosis Scores Compared with Liver Biopsy in Patients with Chronic Hepatitis B.Medicina (Kaunas, Lithuania) · 2026Article
- Machine learning diagnostic framework for liver fibrosis in chronic hepatitis B based on routine laboratory tests.Medicine · 2026Article
- Article
- Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease.Frontiers in medicine · 2026Article
- LIMITED DIAGNOSTIC ACCURACY OF FIB-4 FOR DETECTING SIGNIFICANT LIVER FIBROSIS IN CHRONIC HEPATITIS B: A CROSS-SECTIONAL STUDY.Arquivos de gastroenterologia · 2026Article
- Albumin-bilirubin score as a practical tool for prognostication in metabolic-associated steatotic liver disease.World journal of hepatology · 2025Article
- Comparative analysis of non-invasive fibrosis markers: Insights from chronic HBV, HBV+HDV, and HCV infections.Infectious medicine · 2025Article
- Gray zone and the need for expansion in chronic hepatitis B: From theory to clinical practice.World journal of hepatology · 2025Review
- Current and Investigational Biomarkers of Liver Disease in HIV-HBV Co-infection.Current HIV/AIDS reports · 2025Review
- The Use of Serum Scoring Systems in Predicting Liver Fibrosis Caused by Chronic Hepatitis B: A Retrospective Case-Control Study.Medicina (Kaunas, Lithuania) · 2025Article
- Comparison of IL-34, Elastography, and Biopsy in the Assessment of Liver Fibrosis in Chronic Hepatitis B.Mediterranean journal of hematology and infectious diseases · 2025Article
- Unravelling risk factors for delayed bleeding following ultrasonography-guided liver biopsy: a retrospective analysis.Translational gastroenterology and hepatology · 2025Article
- Epidemiological and clinical profile of hepatitis B infection in ART-naïve people living with HIV in Maputo, Mozambique: a cross-sectional study.BMJ public health · 2025Article
- New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?Journal of personalized medicine · 2024Review
- A New Assessment of Two Transferase-Based Liver Enzymes in Low- and High-Fibrosis Patients Chronically Infected with Hepatitis B Virus: A Meta-Analysis and Pilot Study.Journal of clinical medicine · 2024Article
- Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to provide updated information on the clinical use of non-invasive serum and imaging-based tests for fibrosis assessment in chronic hepatitis B (CHB) virus infection. In recent years, non-invasive tests (NIT) have been increasingly used to determine eligibility for treatment. Liver biopsy is still considered the gold standard for assessing inflammatory activity and fibrosis staging, but it is an invasive procedure with inherent limitations. Simple serum markers such as APRI and FIB-4 are limited by indeterminate results but remain useful initial tests for fibrosis severity if imaging elastography is not available. Point-of-care US-based elastography techniques, such as vibration-controlled transient elastography or 2D shear wave elastography, are increasingly available and have better accuracy than simple serum tests for advanced fibrosis or cirrhosis, although stiffness cut-offs are variable based on E-antigen status and inflammatory activity. Current NITs have poor diagnostic performance for following changes in fibrosis with antiviral therapy. However, NITs may have greater clinical utility for determining prognosis in patients with CHB that have advanced disease, especially for the development of hepatocellular carcinoma and/or liver decompensation. Algorithms combining serum and imaging NITs appear promising for advanced fibrosis and prognostic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.